Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma<subtitle>A Multicenter, Randomized, Double-blind Trial</subtitle>

Abstract

Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.